BRPI0511111A - compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários - Google Patents

compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários

Info

Publication number
BRPI0511111A
BRPI0511111A BRPI0511111-0A BRPI0511111A BRPI0511111A BR PI0511111 A BRPI0511111 A BR PI0511111A BR PI0511111 A BRPI0511111 A BR PI0511111A BR PI0511111 A BRPI0511111 A BR PI0511111A
Authority
BR
Brazil
Prior art keywords
protein kinase
synthesis
kinase inhibitors
compounds
intermediates
Prior art date
Application number
BRPI0511111-0A
Other languages
English (en)
Inventor
Gabriel Martinez-Botella
Michael R Hale
Francois Maltais
Qing Tang
Judth Straub
Original Assignee
Vertex Pharmaceuticals Incorpo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorpo filed Critical Vertex Pharmaceuticals Incorpo
Publication of BRPI0511111A publication Critical patent/BRPI0511111A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

COMPOSTOS DE PIRROL COMO INIBIDORES DE CINASE DE PROTEìNA DE ERK, SUA SìNTESE E SEUS INTERMEDIáRIOS. A presente invenção refere-se a compostos úteis de inibidores de proteína quinase. A invenção também provê composições farmaceuticamente aceitáveis compreendendo os ditos compostos e métodos de uso das composições no tratamento de vários distúrbios, condições ou distúrbios.
BRPI0511111-0A 2004-05-14 2005-05-13 compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários BRPI0511111A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57130904P 2004-05-14 2004-05-14
PCT/US2005/016902 WO2005113541A1 (en) 2004-05-14 2005-05-13 Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto

Publications (1)

Publication Number Publication Date
BRPI0511111A true BRPI0511111A (pt) 2007-11-27

Family

ID=35106760

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511111-0A BRPI0511111A (pt) 2004-05-14 2005-05-13 compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários

Country Status (26)

Country Link
US (6) US7354939B2 (pt)
EP (5) EP1753738B1 (pt)
JP (1) JP5132305B2 (pt)
CN (1) CN1976919A (pt)
AR (2) AR051735A1 (pt)
AU (1) AU2005245885B2 (pt)
BR (1) BRPI0511111A (pt)
CA (1) CA2566461C (pt)
CY (1) CY1122336T1 (pt)
DK (1) DK3305776T3 (pt)
ES (4) ES2513965T3 (pt)
HK (2) HK1203505A1 (pt)
HU (1) HUE047130T2 (pt)
IL (1) IL179207A0 (pt)
LT (1) LT3305776T (pt)
MX (1) MXPA06013209A (pt)
NO (1) NO20065727L (pt)
NZ (1) NZ551582A (pt)
PL (1) PL3305776T3 (pt)
PT (1) PT3305776T (pt)
RU (1) RU2376299C2 (pt)
SI (1) SI3305776T1 (pt)
TW (1) TW200607803A (pt)
UA (1) UA84930C2 (pt)
WO (1) WO2005113541A1 (pt)
ZA (1) ZA200609975B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4808154B2 (ja) * 2003-03-13 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
WO2005100342A1 (en) * 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
EP1753738B1 (en) * 2004-05-14 2014-07-09 Vertex Pharmaceuticals Inc. Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ES2353437T3 (es) 2006-02-16 2011-03-02 Schering Corporation Derivados de pirrolidina como inhibidores de erk.
BRPI0812450A2 (pt) * 2007-06-05 2019-09-24 Schering Corp derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer
NZ587504A (en) 2008-02-21 2012-09-28 Merck Sharp & Dohme Benzopyrazole derivatives as ERK inhibitors
CN102146074B (zh) * 2011-01-26 2013-02-06 江苏先声药物研究有限公司 吡咯衍生物的制备方法及应用
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
WO2015057736A1 (en) 2013-10-14 2015-04-23 Indiana University Research And Technology Corporation Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015095835A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers
WO2015095831A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mtor and erk inhibitors
JP6678584B2 (ja) * 2013-12-20 2020-04-22 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｃｄｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
WO2015095825A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2015095833A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
EP3082800B1 (en) * 2013-12-20 2022-02-02 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
EP3082957B1 (en) * 2013-12-20 2022-04-06 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
WO2015095838A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mek type i and erk inhibitors
CN116854662A (zh) * 2015-01-30 2023-10-10 生物医学谷探索股份有限公司 C21H22Cl2N4O2的晶型
WO2016123581A1 (en) * 2015-01-30 2016-08-04 Biomed Valley Discoveries, Inc. Crystalline c21h22c12n4o2 malonate
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
AU2015396809B2 (en) * 2015-06-03 2019-07-11 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
WO2016192063A1 (en) * 2015-06-03 2016-12-08 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as erk inhibitors
IL291017B2 (en) 2015-10-21 2023-11-01 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
CN109890827A (zh) 2016-10-05 2019-06-14 芝诺罗耶尔蒂里程碑有限责任公司 螺环化合物
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019073435A1 (en) * 2017-10-12 2019-04-18 Novartis Ag COMBINATIONS OF MDM2 INHIBITORS WITH ERK INHIBITORS TO TREAT CANCERS
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2023169480A1 (zh) * 2022-03-08 2023-09-14 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
TW202400572A (zh) * 2022-03-24 2024-01-01 美商生物醫學谷探索公司 Erk的吡咯抑制劑之氘化類似物、其合成及其中間物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5565413A (en) * 1994-12-06 1996-10-15 Zeneca Limited Substituted pyridyl phenyl ketone herbicides
US5472966A (en) * 1995-03-29 1995-12-05 Bristol-Myers Squibb Company Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CA2383492A1 (en) 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Acylhydrazine derivatives, their production and use
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1506189A1 (en) * 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
EP1546121B1 (en) * 2002-07-18 2012-08-29 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
BR0313397A (pt) * 2002-08-14 2005-06-28 Vertex Pharmaceuticals Incorpo Inibidores de proteina cinase e usos destes
JP4808154B2 (ja) 2003-03-13 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
EP1753738B1 (en) * 2004-05-14 2014-07-09 Vertex Pharmaceuticals Inc. Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds

Also Published As

Publication number Publication date
HK1203505A1 (en) 2015-10-30
AU2005245885B2 (en) 2011-01-20
NO20065727L (no) 2006-12-12
CA2566461A1 (en) 2005-12-01
PL3305776T3 (pl) 2020-03-31
USRE49500E1 (en) 2023-04-25
SI3305776T1 (sl) 2020-01-31
US7354939B2 (en) 2008-04-08
ES2897422T3 (es) 2022-03-01
DK3305776T3 (da) 2019-12-09
EP1753738A1 (en) 2007-02-21
CA2566461C (en) 2012-07-10
AR106755A2 (es) 2018-02-14
MXPA06013209A (es) 2007-01-16
RU2376299C2 (ru) 2009-12-20
IL179207A0 (en) 2007-03-08
CN1976919A (zh) 2007-06-06
PT3305776T (pt) 2019-12-17
AR051735A1 (es) 2007-02-07
ES2651439T3 (es) 2018-01-26
JP5132305B2 (ja) 2013-01-30
LT3305776T (lt) 2020-01-10
ES2751761T3 (es) 2020-04-01
RU2006144445A (ru) 2008-06-20
HK1247910A1 (zh) 2018-10-05
EP2799434B1 (en) 2017-08-02
ES2513965T3 (es) 2014-10-27
USRE47318E1 (en) 2019-03-26
CY1122336T1 (el) 2021-01-27
EP1753738B1 (en) 2014-07-09
WO2005113541A1 (en) 2005-12-01
USRE48266E1 (en) 2020-10-20
TW200607803A (en) 2006-03-01
UA84930C2 (ru) 2008-12-10
EP3608315B1 (en) 2021-08-11
EP2799434A1 (en) 2014-11-05
USRE46097E1 (en) 2016-08-09
AU2005245885A1 (en) 2005-12-01
EP3943489A1 (en) 2022-01-26
EP3305776A1 (en) 2018-04-11
EP3305776B1 (en) 2019-09-25
HUE047130T2 (hu) 2020-04-28
EP3608315A1 (en) 2020-02-12
US20060106069A1 (en) 2006-05-18
US20230183276A1 (en) 2023-06-15
NZ551582A (en) 2011-01-28
ZA200609975B (en) 2008-02-27
JP2007537295A (ja) 2007-12-20

Similar Documents

Publication Publication Date Title
BRPI0511111A (pt) compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
BRPI0511124A (pt) pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
EP1597234A4 (en) NEW COMPOUNDS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.